Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma

Supernus Pharmaceuticals

03/08/2026 11:48

Overview
U.S. CNS drugmaker's Q2 revenue rose 32% yr/yr, driven by growth products
Adjusted operating earnings for Q2 beat analyst expectations
Company to merge with Indivior Pharmaceuticals in all-stock deal

Outlook
Supernus raises 2026 total revenue guidance to $860 mln-$890 mln from $840 mln-$870 mln
Company now expects 2026 adjusted operating earnings of $150 mln-$180 mln, up from $140 mln-$170 mln
ONAPGO 2026 net sales forecast maintained at $55 mln-$70 mln

Result Drivers
GROWTH PRODUCTS - Revenue growth was driven by higher net sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO
QELBREE PRESCRIPTION VOLUME - Qelbree net sales rose 15% yr/yr, primarily due to increased prescription volumes in both adult and pediatric populations
ZURZUVAE COLLABORATION REVENUE - Collaboration revenue from ZURZUVAE contributed to growth, with U.S. sales reported by Biogen up 53% yr/yr and prescriptions up 62%

Company press release: ID:nGNX5fl9bn

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Total Net Product Sales
 
$165.70 mln
 
Q2 Total Adjusted Revenue from Commercial Products
 
$201.10 mln
 
Q2 Loss Per Share
 
$1.01
 
Q2 Adjusted Operating Earnings
Beat
$31.20 mln
$18.88 mln (5 Analysts)
Q2 Operating Earnings
 
-$57.96 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $65.00, about 45.6% above its July 31 closing price of $44.63
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads
July 31 - AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
Aug 3 - AstraZeneca investors baulk at $400 billion Bristol Myers talks
July 31 - Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)